Recent News

• 10.02.2025 - Dyne Therapeutics Appoints Brian Posner to its Board of Directors
• 09.29.2025 - Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
• 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.05.2025 - Cantor Global Healthcare Conference 2025
• 08.27.2025 - Dyne Therapeutics to Present at Upcoming Investor Conferences
• 08.04.2025 - Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
• 07.28.2025 - Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Recent Filings

• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 8-K Current report
• 10.02.2025 - 3 Initial statement of beneficial ownership of securities
• 09.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.05.2025 - 144 Report of proposed sale of securities
• 09.04.2025 - 144 Report of proposed sale of securities
• 08.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.04.2025 - 8-K Current report